SLC6A4 and neuroendocrine carcinoma: Furthermore, due to SERT expression in platelets and megakaryocytes and again due to mIBG lacking NET selectivity, mIBG therapy in neuroendocrine cancer is often limited by myelosuppression with low platelet counts [77].